阅读说明：本技术 一种生物标记物在制备用于制备皮肤自荧光检测皮肤癌产品中的方法及其应用 (Method for preparing product for detecting skin cancer by using biological marker in skin autofluorescence and application thereof ) 是由 殷卫海 张铭超 陶钺 李雨嘉 于 2019-01-04 设计创作，主要内容包括：本发明提供了一种生物标记物在制备用于制备皮肤自荧光检测皮肤癌产品中的方法及其应用,所述分子标记物为使用400nm至700nm之间的激发光激发受试者皮肤的自发荧光强度,所述自发荧光的波长范围在420nm至800nm之间。自荧光强度与皮肤癌的严重程度呈正相关,因此通过检测皮肤的该自荧光强度,可以实时无创地检测皮肤癌。根据自发荧光的强度、形态以及左右对称性等性质,我们可以判断患者患皮肤癌分型和分期。(The invention provides a method for preparing a product for detecting skin cancer by skin autofluorescence and an application of a biomarker, wherein the molecular marker is the autofluorescence intensity of the skin of a subject excited by exciting light between 400nm and 700nm, and the wavelength of the autofluorescence is between 420nm and 800 nm. Since the autofluorescence intensity positively correlates with the severity of skin cancer, skin cancer can be detected noninvasively in real time by detecting the autofluorescence intensity of the skin. According to the strength, the form, the left-right symmetry and other properties of the autofluorescence, the classification and the stage of the skin cancer of the patient can be judged.)

1. A method for preparing a product for detecting skin cancer by skin autofluorescence, which comprises the following steps:

(1) the skin is placed under laser with the wavelength within the range of 400-700nm to excite the self-fluorescence of the skin.

(2) Detecting the distribution and intensity of the autofluorescence emitted by the skin within the range of 420-800 nm;

(3) comparing the distribution and intensity of the autofluorescence with that of healthy skin tissue

(4) Judging whether skin cancer exists or not and the degree of the skin cancer, thereby completing the detection method for detecting the skin cancer based on skin autofluorescence.

2. The method of claim 1, wherein:

the tissue autofluorescence intensity of skin cancer focus area is higher than that of cancer side tissue and normal skin tissue.

3. The method of claim 1, wherein:

the fluorescence intensity is increased compared to the autofluorescence of the skin tissue of the focal-free area or compared to the autofluorescence of the skin tissue of healthy people.

4. The method of claim 1, wherein:

the skin cancer comprises squamous cell carcinoma, basal cell carcinoma, malignant melanoma, malignant lymphoma, idiopathic hemorrhagic sarcoma, sweat gland cancer, dermatofibrosarcoma protruberans or angiosarcoma.

5. The method of claim 1, wherein:

the excitation of skin autofluorescence with excitation light includes at least one of excitation with a common continuous light output, modulated excitation with electrical modulation, or excitation with pulsed laser light.

6. The method of claim 1, wherein:

the fluorescence intensity is increased and is positively correlated with the severity of skin cancer; the higher the fluorescence intensity, the higher the severity of skin cancer.

7. Use of a biomarker for the preparation of a product for the autofluorescence detection of skin cancer in the skin, wherein the molecular marker is the skin of a subject excited with excitation light in the range of 400nm to 700nm, and the autofluorescence has an autofluorescence distribution and intensity in the range of 420nm to 800 nm; comparing the distribution and intensity of the autofluorescence with the distribution and intensity of autofluorescence of healthy skin tissue; judging whether skin cancer exists or not and judging the degree of the skin cancer.

Technical Field

The invention relates to a biological fluorescent substance for detecting skin cancer based on skin autofluorescence, in particular to a method for detecting skin cancer based on detecting the autofluorescence intensity of skin tissues and application thereof.

Background

Current methods of detecting skin cancer are commonly performed by taking a skin tissue sample for staining or testing for blood. The former are invasive and long lasting, or of limited accuracy and degree of differentiation between different diseases. Therefore, the method is very important for finding a biological index for real-time noninvasive rapid detection of skin cancer, and has great social and economic significance and clinical significance.

Disclosure of Invention

The present inventors have found that a novel biomarker for a skin cancer detection method can be detected using autofluorescence of skin tissue. Thus, a method is proposed which can be used for the skin cancer detection based on skin autofluorescence.

According to the invention, after the living skin is treated by lipopolysaccharide, the skin autofluorescence is obviously increased, and the result is used as a biological index for detecting skin cancer based on the skin autofluorescence. Establishing a novel method and application for detecting skin cancer.

The specific technical scheme of the invention is as follows:

1. a method for preparing a product for detecting skin cancer by skin autofluorescence is disclosed, which comprises the following steps:

(1) the skin is placed under laser with the wavelength within the range of 400-700nm to excite the self-fluorescence of the skin.

(2) Detecting the distribution and intensity of the autofluorescence emitted by the skin within the range of 420-800 nm;

(3) comparing the distribution and intensity of the autofluorescence with that of healthy skin tissue

(4) Judging whether skin cancer exists or not and the degree of the skin cancer, thereby completing the detection method for detecting the skin cancer based on skin autofluorescence.

Further, the skin includes any one of cells, animal tissues and human tissues.

Further, the experimental method does not require any marking of the skin.

Further, in the detection method of the present invention, the wavelength of the excitation light is preferably in the range of 420-680nm, and more preferably in the range of 460-643 nm.

In the detection method of the present invention, the wavelength of the detected autofluorescence is preferably within the range of 440-750nm, and more preferably within the range of 450-741 nm.

Further, the skin cancer includes, but is not limited to, squamous cell carcinoma, basal cell carcinoma, malignant melanoma, malignant lymphoma, idiopathic hemorrhagic sarcoma, sweat gland cancer, dermatofibrosarcoma protruberans and angiosarcoma.

Further, the excitation of skin autofluorescence with excitation light includes at least one of excitation with a normal continuous light output, modulation excitation with electrical modulation, or excitation with pulsed laser.

Further, the wavelength of the exciting light is within the range of 400-700 nm.

Further, the wavelength of the self-fluorescence is in the range of 420-800 nm.

Further, the fluorescence intensity is increased, which is comparable to the autofluorescence intensity of skin tissue in an area without focal zones. And also can be compared with the self-fluorescence of skin tissues of healthy people.

Further, the fluorescence intensity is increased, and is positively correlated with the severity of skin cancer. The higher the fluorescence intensity, the higher the severity of skin cancer.

The invention also provides application of the biomarker in preparing a product for detecting skin cancer by skin autofluorescence.

Each skin cancer has its own unique autofluorescence intensity, morphology, and bilateral symmetry. According to the invention, the classification and the stage of the skin cancer of the patient can be non-invasively and rapidly judged according to the strength, the form, the bilateral symmetry and other properties of the autofluorescence.

Drawings

FIG. 1: the excitation light 488nm excites the skin to self-fluoresce and receives the receiving light with the wavelength range of 500-550 nm. The autofluorescence of skin squamous carcinoma lesion tissue is represented by the figure.

FIG. 2: the excitation light 488nm excites the skin to self-fluoresce and receives the receiving light with the wavelength range of 500-550 nm. The autofluorescence of the skin cancer lesion tissue is represented by the graph.

Detailed Description

The present invention will be further illustrated by the following detailed description.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

The term "autofluorescence" as used herein means the phenomenon in which a biomolecule, when irradiated with excitation light of an appropriate wavelength, absorbs the energy of the excitation light into an excited state and then exits the excited state to emit light of a wavelength longer than that of the excitation light.

The term "excitation light" as used in the present invention means light capable of exciting a biomolecule to undergo autofluorescence, and the wavelength should be shorter than the autofluorescence

The term "skin cancer" as used herein, is meant to include, but is not limited to, the following diseases: squamous cell carcinoma, basal cell carcinoma, malignant melanoma, malignant lymphoma, idiopathic hemorrhagic sarcoma, sweat gland carcinoma, dermatofibrosarcoma protruberans, and angiosarcoma.

The inventors have conducted a number of experiments to determine the relationship between skin autofluorescence and skin cancer.